Effect of adjustments to dose/timing of immunomodulatory drugs on serologic response to the COVID-19 vaccine
| Drug | N | Total without antibody response (%) | Total with antibody response (%) | No adjust (% of subgroup) | Adjust (% of subgroup) | No adjust mean Ab* (SD) | Adjust mean Ab* (SD) | P value | ||
| Ab− | Ab+ | Ab− | Ab+ | |||||||
| Methotrexate (all) | 110 | 27 (25%) | 83 (75%) | 16 (27%) | 44 (73%) | 11 (22%) | 39 (78%) | 12.08 (7.83) | 10.76 (7.41) | 0.340 |
| Methotrexate (no biologic or JAKi) | 51 | 10 (20%) | 41 (80%) | 6 (20%) | 24 (80%) | 4 (19%) | 17 (81%) | 12.92 (8.21) | 8.79 (6.09) | 0.087 |
| JAK inhibitor | 23 | 2 (9%) | 21 (91%) | 1 (8%) | 11 (92%) | 1 (9%) | 10 (91%) | 12.62 (7.85) | 17.07 (4.73) | 0.240 |
| Rituximab | 38 | 33 (87%) | 5 (13%) | 24 (89%) | 3 (11%) | 9 (82%) | 2 (18%) | 5.07 (2.55) | 11.28 (12.33) | 1.00 |
| Abatacept | 27 | 13 (48%) | 14 (52%) | 5 (45%) | 6 (55%) | 8 (50%) | 8 (50%) | 10.14 (5.29) | 13.65 (8.81) | 0.340 |
| Abatacept intravenous | 20 | 11 (55%) | 9 (45%) | 4 (67%) | 2 (33%) | 7 (50%) | 7 (50%) | 5.40 (2.95) | 12.74 (9.11) | 0.467 |
| Abatacept subcutaneous | 7 | 2 (29%) | 5 (71%) | 1 (25%) | 4 (75%) | 1 (50%) | 1 (50%) | 12.51 (4.61) | 20.00 (-) | |
* refers only to those patients who were antibody positive